Dupilumab Improves Esophageal Distensibility in Eosinophilic Esophagitis

(MedPage Today) -- The monoclonal antibody dupilumab (Dupixent) led to significant improvements in esophageal distensibility among patients with eosinophilic esophagitis, the randomized REMODEL trial showed. At 24 weeks, patients taking dupilumab...
Source
MedPage Today
Opens original article in a new tab



